Halozyme Thrp Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Halozyme Thrp has an operating margin of 54.3%, meaning the company retains $54 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 40.7% the prior year.
Halozyme Thrp's revenue surged 22.4% year-over-year to $1.0B, reflecting rapid business expansion. This strong growth earns a score of 93/100.
Halozyme Thrp has elevated debt relative to equity (D/E of 4.14), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 7.80, Halozyme Thrp holds $7.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Halozyme Thrp converts 46.1% of revenue into free cash flow ($468.4M). This strong cash generation earns a score of 100/100.
Halozyme Thrp earns a strong 122.1% return on equity (ROE), meaning it generates $122 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is down from 336.0% the prior year.
Halozyme Thrp scores 5.47, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.3B) relative to total liabilities ($1.7B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Halozyme Thrp passes 9 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Halozyme Thrp generates $1.08 in operating cash flow ($479.1M OCF vs $444.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Halozyme Thrp earns $30.5 in operating income for every $1 of interest expense ($551.5M vs $18.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Halozyme Thrp (HALO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Halozyme Thrp generated $1.0B in revenue in fiscal year 2024. This represents an increase of 22.4% from the prior year.
Halozyme Thrp's EBITDA was $561.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.1% from the prior year.
Halozyme Thrp generated $468.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 25.5% from the prior year.
Halozyme Thrp reported $444.1M in net income in fiscal year 2024. This represents an increase of 57.7% from the prior year.
Halozyme Thrp earned $3.43 per diluted share (EPS) in fiscal year 2024. This represents an increase of 63.3% from the prior year.
Halozyme Thrp held $115.8M in cash against $1.5B in long-term debt as of fiscal year 2024.
Halozyme Thrp had 123M shares outstanding in fiscal year 2024. This represents a decrease of 2.9% from the prior year.
Halozyme Thrp's gross margin was 84.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 7.5 percentage points from the prior year.
Halozyme Thrp's operating margin was 54.3% in fiscal year 2024, reflecting core business profitability. This is up 13.6 percentage points from the prior year.
Halozyme Thrp's net profit margin was 43.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 9.8 percentage points from the prior year.
Halozyme Thrp's ROE was 122.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 213.9 percentage points from the prior year.
Halozyme Thrp invested $79.0M in research and development in fiscal year 2024. This represents an increase of 3.5% from the prior year.
Halozyme Thrp spent $250.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 37.9% from the prior year.
Halozyme Thrp invested $10.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 30.1% from the prior year.
HALO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $354.3M+8.8% | $325.7M+23.0% | $264.9M-11.1% | $298.0M+28.8% | $231.4M+18.1% | $195.9M-14.8% | $230.0M+6.5% | $216.0M |
| Cost of Revenue | $55.2M+19.2% | $46.4M-4.2% | $48.4M+15.1% | $42.1M+6.2% | $39.6M+39.8% | $28.3M-45.8% | $52.3M-4.6% | $54.8M |
| Gross Profit | $299.0M+7.0% | $279.4M+29.1% | $216.5M-15.4% | $256.0M+33.5% | $191.7M+14.4% | $167.6M-5.7% | $177.7M+10.3% | $161.2M |
| R&D Expenses | $17.3M-1.7% | $17.5M+18.5% | $14.8M-27.6% | $20.4M-2.8% | $21.0M+10.1% | $19.1M-10.4% | $21.3M+23.2% | $17.3M |
| SG&A Expenses | $46.1M+10.8% | $41.6M-1.8% | $42.4M+0.3% | $42.2M+18.3% | $35.7M+1.6% | $35.1M-6.6% | $37.6M+6.6% | $35.3M |
| Operating Income | $217.9M+7.6% | $202.4M+43.0% | $141.5M-19.4% | $175.5M+49.7% | $117.2M+22.7% | $95.5M-5.4% | $101.0M+14.4% | $88.3M |
| Interest Expense | $4.3M-2.2% | $4.4M-2.9% | $4.5M-0.3% | $4.5M+0.4% | $4.5M+0.4% | $4.5M-13.7% | $5.2M+15.9% | $4.5M |
| Income Tax | $43.7M+9.9% | $39.8M+54.6% | $25.7M-37.5% | $41.2M+68.2% | $24.5M+27.6% | $19.2M+21.7% | $15.8M-20.8% | $19.9M |
| Net Income | $175.2M+6.1% | $165.2M+39.9% | $118.1M-13.8% | $137.0M+46.9% | $93.2M+21.4% | $76.8M-10.0% | $85.4M+4.3% | $81.8M |
| EPS (Diluted) | $1.43+7.5% | $1.33+43.0% | $0.93-12.3% | $1.06+47.2% | $0.72+20.0% | $0.60-6.3% | $0.64+4.9% | $0.61 |
HALO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+8.1% | $2.1B-6.5% | $2.2B+6.4% | $2.1B+4.8% | $2.0B+6.9% | $1.8B+6.2% | $1.7B-8.4% | $1.9B |
| Current Assets | $1.3B+18.4% | $1.1B-11.0% | $1.3B+16.3% | $1.1B+9.9% | $987.8M+13.1% | $873.6M+17.0% | $746.4M-15.1% | $879.0M |
| Cash & Equivalents | $419.7M+578.4% | $61.9M-64.9% | $176.3M+52.2% | $115.8M-38.3% | $187.9M+14.1% | $164.6M+39.1% | $118.4M-56.8% | $274.2M |
| Inventory | $185.8M+2.4% | $181.5M+10.1% | $164.9M+16.2% | $141.9M-11.0% | $159.3M-5.5% | $168.5M+32.1% | $127.6M-1.0% | $128.9M |
| Accounts Receivable | $343.5M+9.0% | $315.1M+3.6% | $304.0M+5.5% | $288.2M+37.0% | $210.4M+13.5% | $185.3M-20.6% | $233.3M+9.0% | $214.0M |
| Goodwill | $416.8M0.0% | $416.8M0.0% | $416.8M0.0% | $416.8M0.0% | $416.8M0.0% | $416.8M0.0% | $416.8M0.0% | $416.8M |
| Total Liabilities | $1.7B-0.2% | $1.7B+0.4% | $1.7B+0.9% | $1.7B+1.2% | $1.7B+1.0% | $1.7B+0.9% | $1.6B+0.4% | $1.6B |
| Current Liabilities | $837.2M+523.5% | $134.3M-10.7% | $150.4M+8.1% | $139.1M+4.3% | $133.4M+1.3% | $131.6M+17.0% | $112.5M-2.3% | $115.2M |
| Long-Term Debt | $800.1M-47.0% | $1.5B+0.1% | $1.5B+0.1% | $1.5B+0.2% | $1.5B+0.1% | $1.5B+0.1% | $1.5B+0.1% | $1.5B |
| Total Equity | $503.9M+51.4% | $332.7M-31.0% | $482.3M+32.6% | $363.8M+25.7% | $289.4M+62.8% | $177.8M+112.2% | $83.8M-66.4% | $249.2M |
| Retained Earnings | $502.1M+39.1% | $361.0M-24.5% | $478.0M+32.8% | $359.9M+38.1% | $260.6M+55.7% | $167.4M+84.8% | $90.5M-59.3% | $222.3M |
HALO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $178.6M+79.1% | $99.7M-35.3% | $154.2M-13.6% | $178.5M+219.9% | $55.8M-56.9% | $129.4M+26.5% | $102.4M-22.7% | $132.4M |
| Capital Expenditures | $3.0M+93.9% | $1.6M+64.5% | $950K-68.9% | $3.1M+18.2% | $2.6M-27.2% | $3.5M+36.6% | $2.6M-11.8% | $2.9M |
| Free Cash Flow | $175.6M+78.9% | $98.1M-36.0% | $153.3M-12.6% | $175.4M+229.7% | $53.2M-57.7% | $125.9M+26.2% | $99.8M-22.9% | $129.5M |
| Investing Cash Flow | $201.6M+137.8% | $84.8M+193.8% | -$90.4M-406.7% | $29.5M+170.1% | -$42.0M+49.2% | -$82.7M-897.2% | -$8.3M+90.1% | -$83.5M |
| Financing Cash Flow | -$22.4M+92.5% | -$299.0M-8902.3% | -$3.3M+98.7% | -$246.4M-2698.8% | $9.5M+2039.1% | -$489K+99.8% | -$249.9M-6194.1% | $4.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $38.9M | N/A | N/A | $250.0M | $0 | $0-100.0% | $252.3M | $0 |
HALO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.4%-1.4pp | 85.8%+4.0pp | 81.7%-4.2pp | 85.9%+3.0pp | 82.9%-2.7pp | 85.5%+8.3pp | 77.3%+2.7pp | 74.6% |
| Operating Margin | 61.5%-0.6pp | 62.2%+8.7pp | 53.4%-5.4pp | 58.9%+8.2pp | 50.7%+1.9pp | 48.8%+4.9pp | 43.9%+3.1pp | 40.9% |
| Net Margin | 49.5%-1.3pp | 50.7%+6.1pp | 44.6%-1.4pp | 46.0%+5.7pp | 40.3%+1.1pp | 39.2%+2.1pp | 37.1%-0.8pp | 37.9% |
| Return on Equity | 34.8%-14.9pp | 49.6%+25.1pp | 24.5%-13.2pp | 37.7%+5.4pp | 32.2%-11.0pp | 43.2%-58.7pp | 101.9%+69.0pp | 32.8% |
| Return on Assets | 7.9%-0.2pp | 8.0%+2.7pp | 5.4%-1.3pp | 6.6%+1.9pp | 4.7%+0.6pp | 4.2%-0.8pp | 4.9%+0.6pp | 4.3% |
| Current Ratio | 1.59-6.8 | 8.36-0.0 | 8.39+0.6 | 7.80+0.4 | 7.41+0.8 | 6.640.0 | 6.64-1.0 | 7.63 |
| Debt-to-Equity | 1.59-2.9 | 4.54+1.4 | 3.13-1.0 | 4.14-1.1 | 5.19-3.2 | 8.44-9.4 | 17.89+11.9 | 6.01 |
| FCF Margin | 49.6%+19.4pp | 30.1%-27.7pp | 57.9%-1.0pp | 58.9%+35.9pp | 23.0%-41.3pp | 64.3%+20.9pp | 43.4%-16.6pp | 59.9% |
Similar Companies
Frequently Asked Questions
What is Halozyme Thrp's annual revenue?
Halozyme Thrp (HALO) reported $1.0B in total revenue for fiscal year 2024. This represents a 22.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Halozyme Thrp's revenue growing?
Halozyme Thrp (HALO) revenue grew by 22.4% year-over-year, from $829.3M to $1.0B in fiscal year 2024.
Is Halozyme Thrp profitable?
Yes, Halozyme Thrp (HALO) reported a net income of $444.1M in fiscal year 2024, with a net profit margin of 43.7%.
What is Halozyme Thrp's earnings per share (EPS)?
Halozyme Thrp (HALO) reported diluted earnings per share of $3.43 for fiscal year 2024. This represents a 63.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Halozyme Thrp's EBITDA?
Halozyme Thrp (HALO) had EBITDA of $561.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Halozyme Thrp have?
As of fiscal year 2024, Halozyme Thrp (HALO) had $115.8M in cash and equivalents against $1.5B in long-term debt.
What is Halozyme Thrp's gross margin?
Halozyme Thrp (HALO) had a gross margin of 84.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Halozyme Thrp's operating margin?
Halozyme Thrp (HALO) had an operating margin of 54.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Halozyme Thrp's net profit margin?
Halozyme Thrp (HALO) had a net profit margin of 43.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Halozyme Thrp's return on equity (ROE)?
Halozyme Thrp (HALO) has a return on equity of 122.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Halozyme Thrp's free cash flow?
Halozyme Thrp (HALO) generated $468.4M in free cash flow during fiscal year 2024. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Halozyme Thrp's operating cash flow?
Halozyme Thrp (HALO) generated $479.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Halozyme Thrp's total assets?
Halozyme Thrp (HALO) had $2.1B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Halozyme Thrp's capital expenditures?
Halozyme Thrp (HALO) invested $10.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Halozyme Thrp spend on research and development?
Halozyme Thrp (HALO) invested $79.0M in research and development during fiscal year 2024.
Does Halozyme Thrp buy back shares?
Yes, Halozyme Thrp (HALO) spent $250.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Halozyme Thrp have outstanding?
Halozyme Thrp (HALO) had 123M shares outstanding as of fiscal year 2024.
What is Halozyme Thrp's current ratio?
Halozyme Thrp (HALO) had a current ratio of 7.80 as of fiscal year 2024, which is generally considered healthy.
What is Halozyme Thrp's debt-to-equity ratio?
Halozyme Thrp (HALO) had a debt-to-equity ratio of 4.14 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Halozyme Thrp's return on assets (ROA)?
Halozyme Thrp (HALO) had a return on assets of 21.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Halozyme Thrp's Altman Z-Score?
Halozyme Thrp (HALO) has an Altman Z-Score of 5.47, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Halozyme Thrp's Piotroski F-Score?
Halozyme Thrp (HALO) has a Piotroski F-Score of 9 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Halozyme Thrp's earnings high quality?
Halozyme Thrp (HALO) has an earnings quality ratio of 1.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Halozyme Thrp cover its interest payments?
Halozyme Thrp (HALO) has an interest coverage ratio of 30.5x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Halozyme Thrp?
Halozyme Thrp (HALO) scores 82 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.